Health Canada, Canada’s governmental health agency, announced that there is now an option for all biological and pharmaceutical new drug submissions to request aligned regulatory reviews between Health Canada and health technology assessment (HTA) organizations.
Health Canada (HC), Canada’s governmental health agency, announced that there is now an option for all biological and pharmaceutical new drug submissions to request aligned regulatory reviews between HC and health technology assessment (HTA) organizations. The HTAs that are collaborating on the aligned review process are the Canadian Agency for Drugs and Technologies in Health (CADTH) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS).
The HC notice applies to biosimilars, supplemental new drug submissions for new indications when the sponsor intends to seek a coverage recommendation from HTAs on a pre-Notice of Compliance (NOC) basis. The HC policy, effective immediately, formalizes the timelines, process, and considerations for sponsors with qualifying drug submissions and applies to drug sponsors who are “interested in taking part in aligned reviews between HC and HTAs.” The new joint process furthers efforts to reduce the time between market authorization and reimbursement recommendations for public drug plans in order to support affordability, accessibility, and appropriate use of prescription drugs in Canada.
Sponsors of qualifying submissions will be able to opt in to an aligned review pathway at any stage of the review process by completing the template authorizing, sharing of information, and submitting it to HC. HC encourages sponsors to opt in as early as possible in the review process, however. Sponsors must also comply with the advance notice requirement of HTAs.
Sponsors can also use the principles, which HC will apply to all aligned reviews, as a guide when developing applications, including limitations on the sharing of confidential information, independent decision making, and transparency. These principles include:
The initiative’s key benefits include reducing delays between HC’s approval of a drug and the recommendations that CADTH and INESSS issue to advise public drug plans about how drugs should be reimbursed, and improving communication between the organizations and allowing for real-time discussions that can help reduce duplication.
HC hopes the new initiative will further the commonly held goal of helping ensure that all Canadians have access to effective therapies that bring value to patients and the health system. Greater collaboration can help close gaps, reduce delays, and enhance the management of pharmaceuticals in Canada.
In the coming months HC, CADTH, and INESSS will release a webinar to provide interested parties with more information about the process.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.